- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 10: The Important Distinction Between Diagnostic, Screening Tests
There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making-although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.
There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making—although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.
He added that he’s always surprised to learn the lack of medical history that is taken, for example, in conjunction with a BRCA1 or BRCA2 test.
“It feels like we’ve still got a long way to go in creating some accountability and a measurement system and education system to get people ordering them thoughtfully,” Dr Loy said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
